EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Lipid Nanoparticles for Nucleic Acid Delivery to Endothelial Cells

Gary W Liu, Edward B Guzman, Nandita Menon, Robert S Langer

Pharmaceutical Research · 2023

DOI: 10.1007/s11095-023-03471-7 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutical Research, 2023. Verfasst von Gary W Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA. Hauptthemen laut MEDLINE: Nucleic Acids, Nanoparticles. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 264 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Endothelial cells play critical roles in circulatory homeostasis and are also the gateway to the major organs of the body. Dysfunction, injury, and gene expression profiles of these cells can cause, or are caused by, prevalent chronic diseases such as diabetes, cardiovascular disease, and cancer. Modulation of gene expression within endothelial cells could therefore be therapeutically strategic in treating longstanding disease challenges. Lipid nanoparticles (LNP) have emerged as potent, scalable, and tunable carrier systems for delivering nucleic acids, making them attractive vehicles for gene delivery to endothelial cells. Here, we discuss the functions of endothelial cells and highlight some receptors that are upregulated during health and disease. Examples and applications of DNA, mRNA, circRNA, saRNA, siRNA, shRNA, miRNA, and ASO delivery to endothelial cells and their targets are reviewed, as well as LNP composition and morphology, formulation strategies, target proteins, and biomechanical factors that modulate endothelial cell targeting. Finally, we discuss FDA-approved LNPs as well as LNPs that have been tested in clinical trials and their challenges, and provide some perspectives as to how to surmount those challenges.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nucleic AcidsNanoparticlesEndothelial CellsLiposomesGene Transfer TechniquesRNA, Small Interfering

Stichwörter der Autor:innen

endothelial cellsgene deliverylipid nanoparticlenanoparticlesnucleic acids

Substanzen

Lipid NanoparticlesNucleic AcidsLiposomesRNA, Small Interfering

Autor:innen und Institutionen

  • Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
  • Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
  • School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, 02138, USA.
  • Strand Therapeutics, MA, 02215, Boston, USA.
  • Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA. rlanger@mit.edu.

Förderung

  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Liu, G. W., Guzman, E. B., Menon, N., & Langer, R. S. (2023). Lipid Nanoparticles for Nucleic Acid Delivery to Endothelial Cells. Pharmaceutical Research. https://doi.org/10.1007/s11095-023-03471-7

Vancouver

Liu GW, Guzman EB, Menon N, Langer RS. Lipid Nanoparticles for Nucleic Acid Delivery to Endothelial Cells. Pharmaceutical Research. 2023. doi:10.1007/s11095-023-03471-7

BibTeX
@article{Liu2023,
  author = {Liu, Gary W and Guzman, Edward B and Menon, Nandita and Langer, Robert S},
  title = {Lipid Nanoparticles for Nucleic Acid Delivery to Endothelial Cells},
  journal = {Pharmaceutical Research},
  year = {2023},
  doi = {10.1007/s11095-023-03471-7}
}
Kostenlos starten →